The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Open accessAbstract
A series of antisense oligonucleotides (ASOs) containing either 2'-O-methoxyethylribose (MOE) or locked nucleic acid (LNA) modifications were designed to investigate whether LNA antisense oligonucleotides (ASOs) have the potential to improve upon MOE based ASO therapeutics. Some, but not all, LNA containing oligonucleotides increased potency for reducing target mRNA in mouse liver up to 5-fold relative to the corresponding MOE containing ASOs. However, they also showed profound hepatotoxicity as measured by serum transaminases, organ weights and body weights. This toxicity was evident for multiple sequences targeting three different biological targets, as well as in mismatch control sequences having no known mRNA targets. Histopathological evaluation of tissues from LNA treated animals confirmed the hepatocellular involvement. Toxicity was observed as early as 4 days after a single administration. In contrast, the corresponding MOE ASOs showed no evidence for toxicity while maintaining the ability to reduce target mRNA. These studies suggest that while LNA ASOs have the potential to improve potency, they impose a significant risk of hepatotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“The upregulation of the pro-apoptotic protein Bax suggests involvement of the p53-mediated apoptosis pathway, as Bax is a key response gene to p53 activation (42,43).”
Backgroundp53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
Self-citationObika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700
Obika, S., Nanbu, D., Hari, Y., Morio, K.-I., In, Y., Ishida, T., & Imanishi, T. (1997) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)10322-7 · Cited by 610
Physicochemical properties of phospborothioate oligodeoxynucleotides
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.8.3209 · Cited by 591
Chiang, M. Y., Chan, H., Zounes, M. A., Freier, S. M., Lima, W. F., & Bennett, C. F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55250-9 · Cited by 463
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461
Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142298199 · Cited by 414
Self-citationPhosphorothioate Oligodeoxynucleotides: What Is Their Origin and What Is Unique About Them?
ECKSTEIN, F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.117 · Cited by 382
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 358
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
LNA (Locked Nucleic Acid): An RNA Mimic Forming Exceedingly Stable LNA:LNA Duplexes
Koshkin, A. A., Nielsen, P., Meldgaard, M., Rajwanshi, V. K., Singh, S. K., & Wengel, J. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9822862 · Cited by 338
Wengel, J. (1999) · Accounts of Chemical Research · doi:10.1021/ar980051p · Cited by 335
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., & Levin, A. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38831-7 · Cited by 288
Zhang, H., Cook, J., Nickel, J., Yu, R., Stecker, K., Myers, K., & Dean, N. M. (2000) · Nature Biotechnology · doi:10.1038/78475 · Cited by 268
Chi, K. N., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., Tu, D., & Gleave, M. E. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji252 · Cited by 266
Dean, N. M., & McKay, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11762 · Cited by 242
Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren Oligonucleotide
Martin, P. (1995) · Helvetica Chimica Acta · doi:10.1002/hlca.19950780219 · Cited by 234
Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 225
McKay, R. A., Miraglia, L. J., Cummins, L. L., Owens, S. R., Sasmor, H., & Dean, N. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1715 · Cited by 220
Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice
Butler, M., McKay, R. A., Popoff, I. J., Gaarde, W. A., Witchell, D., Murray, S. F., Dean, N. M., Bhanot, S., & Monia, B. P. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1028 · Cited by 216
Self-citationStructural Studies of LNA:RNA Duplexes by NMR: Conformations and Implications for RNase H Activity
Bondensgaard, K., Petersen, M. Å., Singh, S. K., Rajwanshi, V. K., Kumar, R., Wengel, J., & Jacobsen, J. P. (2000) · Chemistry - A European Journal · Cited by 196
A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR
Nanduri, S. (2000) · The EMBO Journal · doi:10.1093/emboj/19.20.5567 · Cited by 188
Translation Inhibition in Apoptosis
Saelens, X., Kalai, M., & Vandenabeele, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103674200 · Cited by 179
Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA.
Manoharan, M., Egli, M., Teplova, M., Minasov, G., Tereshko, V. A., Inamati, G. B., & Cook, P. D. (1999) · Nature Structural Biology · doi:10.1038/9304 · Cited by 178
Wu, S., & Kaufman, R. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.2.1291 · Cited by 165
Scheuner, D., Patel, R., Wang, F., Lee, K., Kumar, K. U., Wu, J., Nilsson, A., Karin, M., & Kaufman, R. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603784200 · Cited by 163
Geary, R. S., Yu, R. Z., Watanabe, T., Henry, S. P., Hardee, G. E., Chappell, A., Matson, J., Sasmor, H., Cummins, L., & Levin, A. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1419 · Cited by 162
Quantitation of Phosphorothioate Oligonucleotides in Human Plasma
Leeds, J. M., Graham, M. J., Truong, L., & Cummins, L. L. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0088 · Cited by 143
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
Geary, R. S., Yu, R. Z., & Levin, A. A. (2001) · PubMed · Cited by 133
Sewell, K. L., Geary, R. S., Baker, B. F., Glover, J., Mant, T., Yu, R. Z., Tami, J. A., & Dorr, F. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036749 · Cited by 121
Tissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in Monkeys
Yu, R. Z., Geary, R. S., Monteith, D., Matson, J. E., Truong, L., Fitchett, J. R., & Levin, A. A. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10473 · Cited by 114
Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA
Frieden, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg820 · Cited by 85
Lima, W. F., Nichols, J. G., Wu, H., Prakash, T. P., Migawa, M. T., Wyrzykiewicz, T. K., Bhat, B., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405035200 · Cited by 83
Self-citationYu, R. Z., Zhang, H., Geary, R. S., Graham, M., Masarjian, L., Lemonidis, K. M., Crooke, R. M., Dean, N. M., & Levin, A. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38750-6 · Cited by 72
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01326-0 · Cited by 72
Liang, Y. T., Osborne, M. C., Monia, B. P., Bhanot, S., Watts, L. M., She, P., DeCarlo, S. O., Chen, X., & Demarest, K. T. (2005) · Metabolism · doi:10.1016/j.metabol.2005.01.030 · Cited by 55
Self-citationA DNA damage signal is required for p53 to activate gadd45.
Xiao, G., Chicas, A., Olivier, M., Taya, Y., Tyagi, S., Kramer, F. R., & Bargonetti, J. (2000) · PubMed · Cited by 51
Boyer, D., Cowen, S. J., Danis, R. P., Diamond, J. G., Fish, R. H., Goldstein, D. A., Jaffe, G. J., Lalezari, J. P., Lieberman, R. M., Belfort, R., et al. (2002) · Pure Amsterdam UMC · Cited by 45
Simões‐Wüst, A. P., Hopkins-Donaldson, S., Sigrist, B., Belyanskaya, L. L., Stahel, R. A., & Zangemeister‐Wittke, U. (2004) · Oligonucleotides · doi:10.1089/oli.2004.14.199 · Cited by 36
Sequence-dependent cytotoxicity of second-generation oligonucleotides
Drygin, D. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh997 · Cited by 29
Siwkowski, A. M., Madge, L. A., Koo, S., McMillan, E., Monia, B. P., Pober, J. S., & Baker, B. F. (2004) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)05640-2 · Cited by 14
Self-citationKoizumi, M., Takagi-Sato, M., Okuyama, R., Araki, K., Sun, W., Nakai, D., Tsutsumi, S., & Kawai, K. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.253 · Cited by 13
Ravikumar, V. T., Andrade, M., Carty, R. L., Dan, A., & Barone, S. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.081 · Cited by 11
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Self-citationThe chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Metadata
- Authors
- Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-12-19
- Volume
- 35
- Issue
- 2
- Pages
- 687-700
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2088707712
- Cited by
- 469
- References
- 45
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.